Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 3;58(3):377.
doi: 10.3390/medicina58030377.

Predictive MRI Biomarkers in MS-A Critical Review

Vlad Eugen Tiu  1   2 , Iulian Enache  3 , Cristina Aura Panea  1   2 , Cristina Tiu  1   3 , Bogdan Ovidiu Popescu  1   4
Affiliations
Review

Predictive MRI Biomarkers in MS-A Critical Review

Vlad Eugen Tiu et al. Medicina (Kaunas). .

Abstract

Background and Objectives: In this critical review, we explore the potential use of MRI measurements as prognostic biomarkers in multiple sclerosis (MS) patients, for both conventional measurements and more novel techniques such as magnetization transfer, diffusion tensor, and proton spectroscopy MRI. Materials and Methods: All authors individually and comprehensively reviewed each of the aspects listed below in PubMed, Medline, and Google Scholar. Results: There are numerous MRI metrics that have been proven by clinical studies to hold important prognostic value for MS patients, most of which can be readily obtained from standard 1.5T MRI scans. Conclusions: While some of these parameters have passed the test of time and seem to be associated with a reliable predictive power, some are still better interpreted with caution. We hope this will serve as a reminder of how vast a resource we have on our hands in this versatile tool-it is up to us to make use of it.

Keywords: MRI; biomarkers; multiple sclerosis; prediction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ruggieri S., Pontecorvo S., Tortorella C., Gasperini C. Induction treatment strategy in multiple sclerosis: A review of past experiences and future perspectives. Mult. Scler. Demyelinating Disord. 2018;3:5. doi: 10.1186/s40893-018-0037-7. - DOI
    1. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J. Neurol. Sci. 2009;277:S42–S45. doi: 10.1016/S0022-510X(09)70012-7. - DOI - PubMed
    1. Rieckmann P., Traboulsee A., Devonshire V., Oger J. Escalating immunotherapy of multiple sclerosis. Ther. Adv. Neurol. Disord. 2008;1:181–192. doi: 10.1177/1756285608098359. - DOI - PMC - PubMed
    1. Spelman T., Magyari M., Piehl F., Svenningsson A., Rasmussen P.V., Kant M., Sellebjerg F., Joensen H., Hillert J., Lycke J. Treatment Escalation vs. Immediate Initiation of Highly Effective Treatment for Patients with Relapsing-Remitting Multiple Sclerosis: Data from 2 Different National Strategies. JAMA Neurol. 2021;78:1197–1204. doi: 10.1001/jamaneurol.2021.2738. - DOI - PMC - PubMed
    1. Simpson A., Mowry E.M., Newsome S.D. Early Aggressive Treatment Approaches for Multiple Sclerosis. Curr. Treat. Options Neurol. 2021;23:19. doi: 10.1007/s11940-021-00677-1. - DOI - PMC - PubMed